Relay Therapeutics, Inc.
RLAY
$3.69
$0.288.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 677.00K | 7.68M | 0.00 | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 677.00K | 7.68M | 0.00 | -- | -- |
| Cost of Revenue | 61.47M | 73.81M | 64.43M | 76.62M | 91.99M |
| Gross Profit | -60.80M | -66.13M | -64.43M | -76.62M | -91.99M |
| SG&A Expenses | 13.75M | 18.74M | 20.55M | 19.75M | 20.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.22M | 92.55M | 84.98M | 96.37M | 112.13M |
| Operating Income | -74.55M | -84.87M | -84.98M | -96.37M | -112.13M |
| Income Before Tax | -70.38M | -77.07M | -76.00M | -88.11M | -92.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.38M | -77.07M | -76.00M | -88.11M | -92.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.38M | -77.07M | -76.00M | -88.11M | -92.21M |
| EBIT | -74.55M | -84.87M | -84.98M | -96.37M | -112.13M |
| EBITDA | -73.55M | -83.66M | -83.65M | -95.00M | -110.76M |
| EPS Basic | -0.41 | -0.46 | -0.45 | -0.63 | -0.69 |
| Normalized Basic EPS | -0.25 | -0.28 | -0.28 | -0.39 | -0.49 |
| EPS Diluted | -0.41 | -0.46 | -0.45 | -0.63 | -0.69 |
| Normalized Diluted EPS | -0.25 | -0.28 | -0.28 | -0.39 | -0.49 |
| Average Basic Shares Outstanding | 171.26M | 169.23M | 167.34M | 140.23M | 132.82M |
| Average Diluted Shares Outstanding | 171.26M | 169.23M | 167.34M | 140.23M | 132.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |